Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:KNSA NYSE:OGN NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$7.25+0.5%$6.86$4.25▼$9.85$2.68B0.482.64 million shs276,239 shsKNSAKiniksa Pharmaceuticals International$36.10-2.1%$31.32$17.82▼$37.25$2.67B0.2666,256 shs95,165 shsOGNOrganon & Co.$10.25-1.2%$9.61$8.01▼$21.06$2.66B0.64.42 million shs591,693 shsRZLTRezolute$8.27+2.3%$6.17$2.21▼$8.34$718.15M0.02922,341 shs204,269 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-1.43%-6.05%+25.13%+35.59%+16.64%KNSAKiniksa Pharmaceuticals International+0.79%+7.53%+14.65%+21.97%+53.33%OGNOrganon & Co.-1.05%+10.21%+12.42%+2.57%-48.64%RZLTRezolute+1.64%+12.69%+39.07%+85.75%+52.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$7.25+0.5%$6.86$4.25▼$9.85$2.68B0.482.64 million shs276,239 shsKNSAKiniksa Pharmaceuticals International$36.10-2.1%$31.32$17.82▼$37.25$2.67B0.2666,256 shs95,165 shsOGNOrganon & Co.$10.25-1.2%$9.61$8.01▼$21.06$2.66B0.64.42 million shs591,693 shsRZLTRezolute$8.27+2.3%$6.17$2.21▼$8.34$718.15M0.02922,341 shs204,269 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-1.43%-6.05%+25.13%+35.59%+16.64%KNSAKiniksa Pharmaceuticals International+0.79%+7.53%+14.65%+21.97%+53.33%OGNOrganon & Co.-1.05%+10.21%+12.42%+2.57%-48.64%RZLTRezolute+1.64%+12.69%+39.07%+85.75%+52.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 2.00Hold$9.0024.22% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$41.1714.04% UpsideOGNOrganon & Co. 2.80Moderate Buy$17.3369.19% UpsideRZLTRezolute 3.20Buy$11.6741.12% UpsideCurrent Analyst Ratings BreakdownLatest RZLT, BHC, OGN, and KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.007/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $54.007/21/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$36.007/9/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $42.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.86B0.27$7.63 per share0.95($0.89) per share-8.14KNSAKiniksa Pharmaceuticals International$529.33M5.05N/AN/A$6.60 per share5.47OGNOrganon & Co.$6.40B0.42$4.83 per share2.12$1.83 per share5.60RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M$0.2627.871.55N/A0.99%-852.36%5.25%10/29/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M$0.04901.93144.40N/A0.90%1.05%0.80%11/4/2025 (Estimated)OGNOrganon & Co.$864M$2.693.812.740.9511.15%163.88%6.99%10/30/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)Latest RZLT, BHC, OGN, and KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/18/2025Q4 2025RZLTRezolute-$0.22N/AN/AN/AN/AN/A8/5/2025Q2 2025OGNOrganon & Co.$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion7/30/2025Q2 2025BHCBausch Health Cos$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billion7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.78%N/A2.97%N/ARZLTRezoluteN/AN/AN/AN/AN/ALatest RZLT, BHC, OGN, and KNSA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/5/2025OGNOrganon & Co.quarterly$0.020.9%8/15/20258/15/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos141.901.310.98KNSAKiniksa Pharmaceuticals InternationalN/A3.573.16OGNOrganon & Co.11.981.651.13RZLTRezoluteN/A8.438.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%KNSAKiniksa Pharmaceuticals International53.95%OGNOrganon & Co.77.43%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos19.97%KNSAKiniksa Pharmaceuticals International53.48%OGNOrganon & Co.1.40%RZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.35 million296.39 millionOptionableKNSAKiniksa Pharmaceuticals International22074.11 million34.48 millionOptionableOGNOrganon & Co.4,000259.97 million256.33 millionNot OptionableRZLTRezolute4087.00 million71.00 millionOptionableRZLT, BHC, OGN, and KNSA HeadlinesRecent News About These CompaniesWalleye Capital LLC Decreases Stock Position in Rezolute, Inc. $RZLTSeptember 8 at 3:41 AM | marketbeat.comRezolute, Inc. $RZLT Shares Bought by OMERS ADMINISTRATION CorpSeptember 6, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Earns "Buy" Rating from HC WainwrightSeptember 6, 2025 | americanbankingnews.comRezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Receives "Buy" Rating from HC WainwrightSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Cuts Stock Position in Rezolute, Inc. $RZLTSeptember 4, 2025 | marketbeat.comNantahala Capital Management LLC Sells 1,566,587 Shares of Rezolute, Inc. $RZLTSeptember 3, 2025 | marketbeat.comRezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor HyperinsulinismSeptember 2, 2025 | globenewswire.comRezolute Aligns with FDA on Phase 3 Trial DesignSeptember 2, 2025 | tipranks.comVelan Capital Investment Management LP Reduces Stock Holdings in Rezolute, Inc. $RZLTAugust 31, 2025 | marketbeat.comAffinity Asset Advisors LLC Buys 125,000 Shares of Rezolute, Inc. $RZLTAugust 28, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Hits New 52-Week High - Still a Buy?August 27, 2025 | marketbeat.comRezolute, Inc. to Present at Upcoming Investor Conferences in September 2025August 27, 2025 | quiverquant.comQRezolute to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comRezolute appoints Karnawat as Chief Commercial OfficerAugust 20, 2025 | msn.comRezolute Appoints New Chief Commercial OfficerAugust 20, 2025 | msn.comRezolute (NASDAQ:RZLT) Hits New 52-Week High - What's Next?August 20, 2025 | marketbeat.comRezolute, Inc. Appoints Sunil Karnawat as Chief Commercial Officer to Advance Commercialization of ersodetugAugust 20, 2025 | quiverquant.comQRezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial OfficerAugust 20, 2025 | globenewswire.comAltium Capital Management LLC Has $881,000 Position in Rezolute, Inc. (NASDAQ:RZLT)August 14, 2025 | marketbeat.comRezolute to Participate in the BTIG Virtual Biotechnology ConferenceJuly 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025ACM Research: Why This Chinese Chip Stock Is Just Getting StartedBy Jeffrey Neal Johnson | September 1, 2025RZLT, BHC, OGN, and KNSA Company DescriptionsBausch Health Cos NYSE:BHC$7.24 +0.04 (+0.49%) As of 11:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Kiniksa Pharmaceuticals International NASDAQ:KNSA$36.10 -0.76 (-2.06%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Organon & Co. NYSE:OGN$10.24 -0.13 (-1.21%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Rezolute NASDAQ:RZLT$8.27 +0.19 (+2.31%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market The Quiet Before the Catalyst: Vertical Aerospace's Next Move Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
